伊莱恩·k . Sorg

Ms. Sorg joined Abbott in 2012 as the Vice President of U.S. Immunology, a role she continued when AbbVie separated from Abbott in January 2013. Her responsibilities were expanded in 2016 as Vice President, Immunology and Oncology. In 2019, Ms. Sorg was named President, U.S. Immunology and AbbVie Patient Services. Prior to joining Abbott in 2012, Ms. Sorg served in management roles at Eli Lilly and Company for 23 years.

She currently serves on the Dean’s Advisory Board of the Purdue University College of Pharmacy and Pharmaceutical Sciences. She is a former member of the Biotechnology Innovation Organization (BIO) Health Section Governing Board and served on its Access and Value Committee and Regulatory Environment Committee from 2019-2022. Ms. Sorg also served as a member of the IBM Watson Health Advisory Board.  

Ms. Sorg graduated from Purdue University School of Pharmacy and Pharmaceutical Sciences.

伊莱恩Sorg是高级副总裁AbbVie和总统,美国的商业运作。她领导最大的商业区为企业专注于推进AbbVie商业成功的品牌在美国的投资组合,包括免疫学、肿瘤学、神经科学专业,和眼睛护理。

Sorg女士于2012年加入雅培美国免疫学的副总统,一个角色时,她继续AbbVie分开阿伯特在2013年1月。她的责任是扩大2016年副总统,免疫学,肿瘤。2019年,Sorg女士被任命为总统,美国免疫学和AbbVie病人服务。加入雅培之前2012年,Sorg女士担任管理角色在礼来公司23年了。

她目前是普渡大学的院长顾问委员会药学院和制药科学。她是一个生物技术创新组织的前成员(生物)健康节董事会,其访问和价值委员会和监管环境委员会从2019年到2022年。Sorg女士还担任IBM Watson健康顾问委员会的成员。

Sorg女士毕业于美国普渡大学药学院和制药科学。